Overview

Orgenesis

By identifying and partnering with early-stage biotechnology developers, we bring development of promising new therapies in-house to create a pipeline of POCare Therapies.

We apply know-how in CGT development and production to build long-term opportunities via processing licenses and royalties at the POCare Network level.

Investor Documents

Investor Presentation

See our latest corporate presentation.

View
2019 Annual Filing

See our latest annual filing.

View

Therapies Pipeline

  • Immuno-Oncology
  • Viral Diseases
  • Metabolic & Autoimmune Diseases
  • Vascular & Musculoskeletal Diseases
  • Kidney Diseases
  • Program
  • Indications
  • Research
  • Preclinical
  • IND Enabling Studies
  • Clinical Trials
  • Commercial
Immuno-Oncology
B-ALL, Lymphoma
An advanced monomeric anti-CD19 Chimeric Antigen Receptor T cells (CAR-T) therapy to treat relapsed or refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) patients.
Lung Cancer; Melanoma
An anti-cancer cellular vaccine that utilizes patient antigen presenting cells (APCs) pulsed with relevant cancer cells to target the entire repertoire of tumour cell antigens and elicit immune response against hard to treat cancers.
Solid Tumors; Pancreatic Cancer
An adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) as a personalized cancer treatment platform via infusion of autologous T lymphocytes expanded from tumors. A complementary cellular biomanufacturing platform is being developed based on a novel metabolic sensor to optimize the harvest time and increase therapeutic potential of the T-cells.
B-ALL
A CD19/22 bi-specific CAR-T therapy to treat relapsed or refractory B-ALL patients and possibly reduce the risk of long-term relapse.
Multiple Myeloma, Ovarian Cancer
A CD19/22 bi-specific CAR-T therapy to treat relapsed or refractory B-ALL patients and possibly reduce the risk of long-term relapse.
Viral Diseases
Covid-19 Related ARDS
Ranpirnase is a ribonuclease (RNA) degrading enzyme used to target double-stranded RNA including miRNA precursors that has been developed for use with external genital warts (EGW) and anal displaysia using advanced topical formulation.
HPV: Genital Warts; Anal Dysplasia
Ranpirnase is a ribonuclease (RNA) degrading enzyme used to target double-stranded RNA including miRNA precursors that has been developed for use with external genital warts (EGW) and anal displaysia using advanced topical formulation.
Covid-19 Vaccine
A systemic formulation of Ranpirnase developed as a broad-spectrum antiviral for multiple infectious diseases including human papilloma virus (HPV), human immunodeficiency virus HIV, a range of severe acute respiratory syndromes (SARS) including COVID-19, Ebola and others.
Metabolic & Autoimmune Diseases
Chronic Pancreatitis
Ranpirnase is a ribonuclease (RNA) degrading enzyme used to target double-stranded RNA including miRNA precursors that has been developed for use with external genital warts (EGW) and anal displaysia using advanced topical formulation.
Liver Failure
A systemic formulation of Ranpirnase developed as a broad-spectrum antiviral for multiple infectious diseases including human papilloma virus (HPV), human immunodeficiency virus HIV, a range of severe acute respiratory syndromes (SARS) including COVID-19, Ebola and others.
Atopic Dermatitis; Wound Healing
A systemic formulation of Ranpirnase developed as a broad-spectrum antiviral for multiple infectious diseases including human papilloma virus (HPV), human immunodeficiency virus HIV, a range of severe acute respiratory syndromes (SARS) including COVID-19, Ebola and others.
Vascular & Musculoskeletal Diseases
Osteoarthritis
A regenerative approach to transform patient’s own liver cells into fully functional and physiologically glucose-responsive AIPs designed to provide long-term insulin independence. This potential treatment was awarded orphan drug designation by the FDA with aims to provide a practical cure for Total Pancreatectomy due to chronic pancreatitis.
Erectile Dysfunction, CLI
A regenerative approach to transform patient’s own liver cells into fully functional and physiologically glucose-responsive AIPs designed to provide long-term insulin independence. This potential treatment was awarded orphan drug designation by the FDA with aims to provide a practical cure for Total Pancreatectomy due to chronic pancreatitis.
Musculoskeletal Diseases
Synthetic exosomes/extracellular vesicles that have demonstrated the ability to fuse with cell membranes and deliver intracellular cargo in a similar manner to natural exosomes. Bioxome can carry selected therapeutic cargo inside target cells, to induce a variety of therapeutic applications. Currently developed to treat Kidney and Liver Disorders.
Kidney Diseases
Chronic Kidney Diseases
A regenerative approach to transform patient’s own liver cells into fully functional and physiologically glucose-responsive AIPs designed to provide long-term insulin independence. This potential treatment was awarded orphan drug designation by the FDA with aims to provide a practical cure for Total Pancreatectomy due to chronic pancreatitis.
Acute and Chronic Kidney Diseases
A regenerative approach to transform patient’s own liver cells into fully functional and physiologically glucose-responsive AIPs designed to provide long-term insulin independence. This potential treatment was awarded orphan drug designation by the FDA with aims to provide a practical cure for Total Pancreatectomy due to chronic pancreatitis.

Company Info

Orgenesis Inc. (Corporate Headquarters)
20271 Goldenrod Lane
Germantown, MD 20876
USA

Orgenesis LTD
P.O. Box 4143
Ness-Ziona 7414002
Israel

Orgenesis Biotech
8 HaHaruv St., Bar-Lev Industrial Park
2015600
Israel

Orgenesis Belgium SRL
Novalis Science Park
Rue de la Science 8
B-6900 Marche-en-Famenne

Orgenesis Korea (Office)
South Korea
Gyeonggi-do, Suwon-si, Yeongtong-gu, Gwanggyo-ro 156
Gwanggyo Business Center #704

Orgenesis Korea (GMP Plant)
South Korea
Gyeonggi-do, Suwon-si, Yeongtong-gu, Gwanggyo-ro 107
Gyeonggi Bio Center #403

Industry Classifications

Sector:
Healthcare

Industry:
Biotechnology

NAICS:
Pharmaceutical Preparation Manufacturing (325412)

SIC:
Pharmaceutical Preparations (2834)

Frequently Asked Questions

Our stock is traded on the NASDAQ under the symbol ORGS.
June 5, 2008
August 2011
December 31st
Securities Transfer Corporation
2591 Dallas Parkway
Suite 102
Frisco, TX 75034
T: 469-633-0101
F: 469-633-0088
www.stctransfer.com
PricewaterhouseCoopers
300 Madison Avenue
New York, NY 10017
www.pwc.com
Pearl Cohen Zedek Latzer Baratz
1500 Broadway
New York, NY 10036
T: 646-878-0800